Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability. The compounds represent promising therapeutics for treating chronic pain.
Current treatments of different types of chronic pain are geared towards decreasing inflammation (if it exists) and maximizing pain relief while minimizing side effects associated with each particular drug type. Unfortunately, this has been a difficult goal to achieve and all of the current treatments for chronic pain, particularly pain of neuropathic origin, have significant side effects which limit their usefulness. Recently, drugs targeting cannabinoid receptors have proven efficacious for patients. However, while current clinical treatments with FDA-approved cannabinoid-based analgesic can provide relief from chronic pain symptoms, these treatments also produce several significant central nervous system-mediated side effects.
Dr. Igor Spigelman of UCLA’s School of Dentistry and Dr. Herbert Seltzman, a collaborator at RTI International, have designed small molecules effective in alleviating chronic pain of inflammatory and neuropathic origin without any centrally-mediated side effects. The molecules are peripherally-acting cannabinoid compounds with high affinity for cannabinoid receptors and have been specifically designed to have limited permeability at the blood-brain barrier.
|United States Of America||Issued Patent||9,656,981||05/23/2017||2012-715|